Recruiting Clinical Trials

Displaying 11 - 20 of 227 result(s)
Study Title Condition Phase Location
A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors. Chronic Myelogenous Leukemia Phase 3
  • Country: 
    Argentina
  • Country: 
    Austria
  • Country: 
    Brazil
  • Country: 
A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg/ml and 15 mg/ml) Used Twice-daily in the Treatment of Post-operative Corneal In ... Chronic Ocular Pain Phase 2
  • Country: 
    United States
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Phase 2
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    Czech Republic
  • Country: 
A Participant and Investigator-blinded, Randomized, Placebo-controlled Phase 2a Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Acute Kidney Injury Due to Sepsis Phase 2
  • Country: 
    Belgium
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (VICTORION-Implement) Hypercholesterolemia Not Given
  • Country: 
    Germany
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection (DME, CRTH258B1401) Diabetic Macular Edema Not Given
  • Country: 
    Japan
A Non-interventional Study Evaluating Kesimpta® (Ofatumumab) Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies [KAIROS] Multiple Sclerosis Not Given
  • Country: 
    Germany
Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401) Chronic Myeloid Leukemia Not Given
  • Country: 
    Japan
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL) Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
Understanding the 'Wearing Off' Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians Multiple Sclerosis Not Given
  • Country: 
    Switzerland